B6 hPD-1 Mouse

The B6 hPD-1 mouse model is a genetically engineered knockin strain in which the murine Pdcd1 gene has been replaced by its human counterpart, PD-1 (Programmed Cell Death Protein 1). PD-1 is a crucial immune checkpoint receptor
expressed on activated T cells and other immune cells. It plays a vital role in regulating immune responses by binding to its ligands, PD-L1 and PD-L2, on antigen-presenting cells or tumor cells, suppressing T-cell activation to maintain
immune homeostasis and prevent overactivation.

This strain is a valuable tool for studying the regulation of immune responses and exploring mechanisms of immune tolerance. It enables the preclinical evaluation of humanspecific monoclonal antibodies or other therapeutic agents
targeting PD-1, particularly in immuno-oncology. Researchers can also investigate combination therapies involving PD-1 blockade, such as its use alongside CTLA-4 inhibitors or cancer vaccines. Additionally, this model is relevant for
autoimmune disease and transplant rejection studies, where modulating PD-1 signaling is of therapeutic interest.

The B6 hPD-1 model serves as a critical bridge between murine research and clinical applications, providing insights into the safety, efficacy, and mechanisms of novel immunotherapies targeting PD-1.
This strain was developed by the Shanghai Model Organism Center and licensed to Janvier Labs in 2024. The animals are bred to preserve the genetic background and homozygous mutation of interest, following JANVIER LABS GENETIC
POLICY®.